ResApp Health Limited (ASX: RAP) has recently presented an update on its performance from various studies and approvals received as on November 15, 2018.
While addressing the shareholders, Chief Executive Officer and Managing Director of RAP, Tony Keating, has mentioned all about the progressive growth of RAP towards the commercialization of RAP products. RAP acute respiratory disease diagnostic technology after being validated by over 4500 patients at hospitals in Australia and the United States has now reached to a stage where the company is looking forward to submitting an application for regulatory approvals in Europe, Australia and the United States for paediatric use.
In the year 2018, RAP has made an announcement regarding its obstructive sleep apnoea program. The company continues to maintain its relationship with a number of world-class partners who have provided their strong contribution towards the success of ResApp.Some of them are Dr Abeyrate and his research team at The University of Queensland, Dr Porter and his team at Joondalup Health Campus, Dr Currie and Dr Ling and their team at Cardio Respiratory Sleep along with the three principal investigators of SMARTCOUGH-C-2 and their associated teams at Massachusetts General Hospital, Cleveland Clinic and Texas Children’s Hospital.
ResApp with its technological advancement has focused on providing outputs which will help clinicians to follow a “decision-tree” like process which will narrow down their diagnosis only to a specific disease and treatment especially in the environments of urgent care or telehealth where there is either an unavailability of the tools used at critical points or either their response is slow and imprecise.
The diagnosis path under the clinical decision begins with the major step of differentiating between the upper and the lower respiratory tract disease, using the significant clinical symptoms and signs.
ResApp algorithms can provide quick and accurate answers to such queries with their excellent repeatability. The algorithms also provided invaluable answers during the second phase of diagnosis where an upper or the lower respiratory tract disease was further narrowed down into a single specific diagnosis.
Positive outcomes from the double-blind, prospective paediatric Breathe Easy study further showcased that the ResApp algorithms can very well identify a broad range of respiratory diseases associated with the upper and the lower respiratory tract in children. Outstanding results over the expected ones provides a very strong dataset to underpin ResApp CE mark and TGA submissions which will help to expand the footprints in the large European and Australian markets. The company has recently received ISO 13845 quality system accreditation and is now in the process to complete registration formalities.
The SMARTCOUGH-C-2 study clearly highlighted the challenges with the clinical adjudication for the diagnosis of the respiratory disease.
The company is now completely focused on its acute respiratory disease clinical programs on adults and awaiting results from the prospective adult Breathe Easy study in coming time. ResApp POC (proof of concept) has opened varied opportunities towards the management of chronic respiratory diseases like asthma and chronic obstructive pulmonary disease. As per the recent data around 16 million people in the United States are suffering from COPD, and approximately 100 million in China have COPD, and many are undiagnosed and this provides a huge market for the company to tap and scale up its performance that will contribute to its future growth. It has also received a notice of allowance for a patent on core technology in Japan.
With major regulatory submissions in pipeline, various clinical studies coming to their conclusion and progression of hospital partnership in Germany and shaping up of DARPA-funded project with Lockheed Martin along with the progression of the sleep apnoea program towards the regulatory submission, the company is progressing towards its set goals. With the release of this update the scrip found support near the previous close. As on November 16, 2018, RAP closed at the levels of $0.110, down 4.4% post a 9.5% rise seen in last five trading days.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.